Ultragenyx Pharm Stock Price, News & Analysis

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) reported total revenue of $351.4 million for 2021, with $192.6 million from Crysvita. The company anticipates Crysvita revenue between $250 million and $260 million for 2022. Dojolvi revenue guidance is $55 million to $65 million. The year-end cash balance stands at $1.0 billion. Despite revenue growth, Ultragenyx posted a net loss of $454 million, or $6.70 per share, reflecting increased operating expenses. The company is focused on expanding its clinical pipeline and commercializing Evkeeza in Europe.

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) will host a conference call on February 10, 2022, at 5:00 PM ET to discuss its financial results for Q4 and the full year ended December 31, 2021. The call will detail the company’s performance and corporate updates. A live and replayed webcast will be accessible on the company’s website, ensuring transparency regarding its operations in developing therapies for rare diseases. Ultragenyx focuses on addressing high unmet medical needs with its innovative therapies.

Ultragenyx Pharmaceutical (NASDAQ: RARE) announced the grant of non-qualified stock options for 16,050 shares and 5,350 restricted stock units to two newly hired non-executive officers. These awards, approved by the board's compensation committee, were made under the Ultragenyx Employment Inducement Plan as an inducement to the new hires. The options vest over four years with a starting exercise price of $72.04, equal to the closing stock price on February 1, 2022. The company focuses on developing therapies for rare diseases, aiming for rapid and efficient drug development.

ShouTi Inc., a clinical-stage biopharmaceutical firm, has appointed Daniel Welch as Chairman of its board. Welch brings over 40 years of experience in the pharmaceutical industry, having led companies like InterMune and Triangle Pharmaceuticals. His extensive background in drug development is expected to bolster ShouTi's mission to deliver innovative, small molecule medicines addressing chronic diseases. CEO Raymond Stevens emphasized Welch's invaluable leadership as the company seeks to enhance its impact on patients awaiting life-changing treatments.

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) reported preliminary 2021 revenue for Crysvita of $191-$193 million, exceeding guidance, and Dojolvi revenue of $38-$40 million. For 2022, Crysvita is projected at $250-$260 million, a 33% increase, while Dojolvi is expected between $55-$65 million, reflecting 60% growth. The year-end 2021 cash position stands at approximately $1 billion. The company is focused on commercializing Evkeeza in Europe and advancing clinical programs for rare diseases.

ReCode Therapeutics announced the appointment of Shehnaaz Suliman as CEO and board member, effective immediately. Former CEO David Lockhart transitions to Chief Scientific Officer. Dr. Suliman, with over 25 years in drug development, previously led Alector and held key roles at Theravance and Roche. She aims to advance ReCode's pipeline of genetic medicines utilizing their selective organ targeting platform. The leadership change is anticipated to enhance growth and innovative therapeutics in the biopharmaceutical space.

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) has announced that CEO Emil D. Kakkis will present at the H.C. Wainwright BioConnect Conference on January 13, 2022, at 7:00 AM ET. The presentation will be available via live and archived webcast on the company's website for 90 days. Ultragenyx focuses on developing therapies for rare and ultra-rare genetic diseases, with a portfolio aimed at addressing conditions with high unmet medical needs. The company emphasizes efficient drug development to deliver urgent therapies to patients.

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) and GeneTx Biotherapeutics announced that the first four patients in their Phase 1/2 study of GTX-102, a treatment for Angelman syndrome, have received multiple doses. No serious adverse events were reported, and preliminary assessments indicate early signs of clinical activity. The Data Safety Monitoring Board recommended dose escalation for Cohort 4. Initial improvements in clinical assessments are noted, with further data expected by mid-2022. GTX-102 aims to reactivate the paternal UBE3A allele, addressing symptoms of Angelman syndrome.

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) announced that CEO Emil D. Kakkis will present at the 40th Annual JP Morgan Healthcare Conference on January 10, 2022, at 3:45 PM ET. The presentation will be accessible via a live webcast on the company's website, with a replay available for 90 days afterward. Ultragenyx focuses on developing therapies for serious rare and ultra-rare genetic diseases, boasting a diverse portfolio aimed at high unmet medical needs. The company emphasizes efficient drug development to deliver safe and effective treatments urgently.